Imatinib
- PDF / 130,654 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 80 Downloads / 208 Views
1
S
Philadelphia-negative acute promyelocytic leukaemia: case report A 51-year-old man developed Philadelphia-negative acute promyelocytic leukaemia (APL) after receiving imatinib. The man received imatinib 400mg/day [route not stated] for chronic phase chronic myeloid leukaemia (CML). On his own initiative he discontinued imatinib after 3 years of treatment, due to side effects including mood disorder. A peripheral blood test 11 months after stopping imatinib showed a decrease in his WBC count. Bone marrow aspirate indicated abnormal myelocyte numbers. Cytogenic analysis was carried out; findings indicated that the man had developed APL, although his CML was in complete cytogenic response. The man received remission induction therapy with tretinoin, and consolidation chemotherapy. He subsequently received nilotinib as maintenance therapy for CML; this therapy was alternated with tretinoin. At his last followup he had maintained complete molecular remission in both APL and CML. Author comment: "This is the first case of Ph-negative APL after imatinib treatment for CML." Inokura K, et al. Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor. Annals of Hematology 91: 1825-1826, No. 11, Nov 2012. Available from: URL: http://dx.doi.org/10.1007/s00277-012-1477-3 803081268 Japan
0114-9954/10/1432-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 15 Dec 2012 No. 1432
